UDC: 616-006.44-085.2-06:616.8 doi: 10.5633/amm.2019.0114

## DICHLOROACETATE-INDUCED NEUROPATHY IN HIGH GRADE FOLLICULAR LYMPHOMA PATIENT

Mladen Djordjević<sup>1</sup>, Ivan Petković<sup>2</sup>

 $^1\text{Clinic}$  of Oncology, Department for Hematooncology, Clinical Center Niš, Serbia  $^2\text{University}$  of Niš, Faculty of Medicine, Niš, Serbia

Contact: Mladen Djordjević

Branka Krsmanovića 4/74, 18000 Niš, Serbia E-mail: mladen.djordjevic555@gmail.com

Curative therapy for follicular lymphomas (FLs) has not been established yet. FLs respond well to chemotherapy and radiation. A large number of current studies confirmed an improved overall response if rituximab was added to chemotherapy. Dichloroacetate (DCA) can be used to inhibit tumor growth. There have been reports that DCA leads to neuropathy. In non-Hodgkin's lymphoma (NHL), DCA leads to antineoplastic action against cell lines and apoptosis of tumor cells, which reduces the metabolism and the number of tumor cells. We present a patient with NHL-FL Grade 3a who took alternatively DCA therapy. In our case report, DCA did not show any treatment benefit but only serious sensorimotor neuropathy as a result of DCA therapy.

Acta Medica Medianae 2019;58(1):102-105.

Key words: follicular lymphoma, dichloroacetate, neuropathy